18.14
0.16 (0.89%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Cullinan Therapeutics, Inc. | Bullish | Bullish |
Stockmoo Score
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mpm Bioimpact Llc | 30 Jun 2024 | 7,648,268 |
| 52 Weeks Range | ||
| Median | 36.00 (98.46%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 09 Aug 2024 | 36.00 (98.46%) | Buy | 16.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2024 | Announcement | Cullinan Therapeutics to Participate in Upcoming Investor Conferences |
| 08 Aug 2024 | Announcement | Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |